Compugen Ltd. (NASDAQ:CGEN) Sees Significant Decline in Short Interest

Compugen Ltd. (NASDAQ:CGEN) saw a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 1,270,000 shares, a decrease of 18.1% from the October 15th total of 1,550,000 shares. Based on an average daily volume of 225,400 shares, the short-interest ratio is presently 5.6 days.

Compugen Trading Down 5.4 %

Shares of Compugen stock opened at $1.41 on Friday. Compugen has a 1-year low of $0.61 and a 1-year high of $3.03. The firm’s 50-day moving average price is $1.75 and its two-hundred day moving average price is $1.87. The stock has a market capitalization of $125.82 million, a price-to-earnings ratio of 70.50 and a beta of 2.64.

Compugen (NASDAQ:CGEN) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.20). The business had revenue of $17.13 million for the quarter, compared to analyst estimates of $17.67 million. Compugen had a net margin of 2.67% and a return on equity of 2.62%. During the same period in the prior year, the business earned ($0.11) earnings per share. As a group, equities research analysts predict that Compugen will post 0.07 EPS for the current year.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Compugen from a “hold” rating to a “buy” rating in a research note on Thursday, August 15th.

Institutional Investors Weigh In On Compugen

A number of hedge funds have recently added to or reduced their stakes in CGEN. Atom Investors LP lifted its position in shares of Compugen by 27.5% during the third quarter. Atom Investors LP now owns 151,816 shares of the biotechnology company’s stock worth $275,000 after purchasing an additional 32,701 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Compugen by 82.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 274,335 shares of the biotechnology company’s stock worth $497,000 after buying an additional 124,190 shares in the last quarter. Oppenheimer & Co. Inc. boosted its position in Compugen by 75.9% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 19,350 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 8,350 shares during the last quarter. Joel Isaacson & Co. LLC increased its stake in shares of Compugen by 136.4% in the 3rd quarter. Joel Isaacson & Co. LLC now owns 52,000 shares of the biotechnology company’s stock valued at $94,000 after buying an additional 30,000 shares during the period. Finally, Squarepoint Ops LLC raised its position in shares of Compugen by 23.4% during the second quarter. Squarepoint Ops LLC now owns 85,693 shares of the biotechnology company’s stock worth $144,000 after acquiring an additional 16,253 shares during the last quarter. Institutional investors own 12.22% of the company’s stock.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.